Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2025-10-29 Governance Information
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
董事会秘书工作细则（2025年第一次修订）
Governance Information Classification · 95% confidence The document is titled '董事会秘书工作细则（2025年第一次修订）' which translates to 'Board Secretary Work Rules (First Revision in 2025)'. It details the qualifications, duties, appointment, and procedures related to the company's board secretary. The content is about internal governance rules and procedures rather than financial results, audit, or announcements of meetings or votes. It is a governance-related document outlining internal rules and responsibilities of a key board officer. There is no indication of financial data, voting results, or meeting materials. Therefore, the document fits best under Governance Information (CGR). The document length is about 5031 characters, which is sufficient for a detailed governance report rather than a brief announcement or notice.
2025-10-29 Chinese
第五届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 12th meeting of the 5th Supervisory Board of Beijing Kangle Weishi Biotechnology Co., Ltd. It details meeting attendance, agenda items, and voting results on various company matters such as the approval of the 2025 Q3 report, change of accounting firm, acceptance of financial support from a controlling shareholder, and amendments to company bylaws. The document does not contain the actual quarterly report or financial statements but references that the 2025 Q3 report is disclosed separately on the Beijing Stock Exchange information platform. The document is a meeting resolution announcement rather than the report itself. It also includes voting results on these resolutions but is not a shareholder vote result announcement per se. Given the nature of the content—meeting resolutions and approvals by the supervisory board—the best fitting category is Regulatory Filings (RNS), as it is a regulatory announcement of meeting decisions without the full report or detailed financial data included.
2025-10-29 Chinese
第五届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 12th meeting of the 5th Board of Directors of Beijing Kangle Weishi Biotechnology Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to other announcements and reports published on the Beijing Stock Exchange information disclosure platform. The document discusses approval of the 2025 Q3 report, change of auditor, financial support from controlling shareholder, amendments to company bylaws, and internal management system revisions. It is a formal board meeting resolution announcement rather than the actual quarterly report or audit report itself. The document length is about 4008 characters, which is relatively short and consistent with a meeting resolution announcement. It does not contain substantive financial data or full report content but references other filings for detailed reports. Therefore, this document fits best into the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2025-10-29 Chinese
关于召开2025年第二次临时股东会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a detailed notice for the 2025 second extraordinary general meeting of shareholders of Beijing Kangle Weishi Biotechnology Co., Ltd. It includes information about the meeting date, voting methods (including online voting), agenda items to be voted on, registration procedures, and proxy authorization forms. The content focuses on the announcement and organization of a shareholders' meeting rather than the results of voting or the meeting minutes. It is not a report of voting results, nor is it a full annual or interim report, audit report, or earnings release. The document is not a proxy solicitation but a formal meeting notice. Therefore, the document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings, including notices of meetings and related materials.
2025-10-29 Chinese
董事会议事规则（2025年第一次修订）
Governance Information Classification · 95% confidence The document is titled "董事会议事规则（2025年第一次修订）" which translates to "Board Meeting Rules (First Revision in 2025)". It details the rules and procedures for the company's board meetings, including the composition of the board, powers of the board and chairman, meeting convocations, voting procedures, and other governance-related matters. It references company laws, stock exchange listing rules, and internal company articles. There is no financial data, earnings information, or shareholder voting results. The document is a governance-related internal rules update rather than a report or announcement of financial results or shareholder votes. Therefore, it fits the category of Governance Information (CGR). The document length (8475 characters) supports it being a full governance document rather than a brief announcement.
2025-10-29 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2025 年第三季度报告" which translates to "2025 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the quarter ending September 30, 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period. It is unaudited, which is common for interim or quarterly reports. The length of the document (15,000 characters) and the presence of detailed financial data confirm it is a full interim report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-29 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.